Elanco Animal Health Enters Material Definitive Agreement

Ticker: ELAN · Form: 8-K · Filed: 2024-08-13T00:00:00.000Z

Sentiment: neutral

Topics: material-definitive-agreement, financial-obligation

TL;DR

Elanco just signed a big deal, could affect their cash flow.

AI Summary

Elanco Animal Health Inc. entered into a material definitive agreement on August 13, 2024, related to a financial obligation. The company, headquartered in Greenfield, Indiana, filed a Form 8-K to report this event. Specific details of the agreement and the financial obligation are not fully disclosed in the provided text, but it is a significant event requiring SEC reporting.

Why It Matters

This filing indicates a significant financial commitment or agreement by Elanco Animal Health, which could impact its future financial obligations and operational strategies.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new financial obligations or strategic shifts that carry inherent business risks.

Key Players & Entities

FAQ

What type of material definitive agreement did Elanco Animal Health enter into?

The filing states Elanco Animal Health Incorporated entered into a material definitive agreement, but the specific nature of the agreement is not detailed in the provided text.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is August 13, 2024.

Where are Elanco Animal Health's principal executive offices located?

Elanco Animal Health's principal executive offices are located at 2500 Innovation Way, Greenfield, Indiana, 46140.

What is Elanco Animal Health's IRS Employer Identification Number?

Elanco Animal Health's IRS Employer Identification Number is 82-5497352.

What SEC Act is this filing made pursuant to?

This filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

From the Filing

0001104659-24-089000.txt : 20240813 0001104659-24-089000.hdr.sgml : 20240813 20240813163252 ACCESSION NUMBER: 0001104659-24-089000 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240813 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240813 DATE AS OF CHANGE: 20240813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 241202227 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 8-K 1 tm2421451d1_8k.htm FORM 8-K false 0001739104 0001739104 2024-08-13 2024-08-13 0001739104 us-gaap:CommonStockMember 2024-08-13 2024-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES   SECURITIES AND EXCHANGE COMMISSION Washington , D. C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported) : August 13, 2024   Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter)   Indiana   001-38661   82-5497352 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S Employer Identification No.)   2500 Innovation Way Greenfield , Indiana (Address of principal executive offices)   46140 (Zip Code)   Registrant’s telephone number, including area code: ( 877 ) 352-6261   Not Applicable (Former Name or Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, no par value   ELAN   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   ¨   Emerging growth company   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 1.01 Entry into a Material Definitive Agreement.   On August 13, 2024 , Elanco Animal Health Incorporated (the “Company”), Elanco US Inc. and certain subsidiaries of the Company entered into an incremental assumption agreement (the “Incremental Assumption Agreement”) with Farm Credit Mid-America, PCA, as incremental term lender, and Goldman Sachs Bank USA, as the term facility age

View on Read The Filing